NOX receives 2018/19 Federal Government R&D tax rebate

23 August 2019

Sydney, Australia. Noxopharm Limited (ASX: NOX) is pleased to announce that it has received
$3.71M cash rebate as part of the Federal Government R&D Tax Incentive Scheme.

Greg van Wyk, Noxopharm Chief Executive Officer, said, ‘The support we receive from the
Australian Government, by way of the R&D rebate scheme, is a key factor in enabling us to
conduct high quality research with Australian scientific partners and be able to select partners in
other jurisdictions. We are grateful for this support.’

‘This year’s rebate helps to put the Company in a solid financial position to finish the 2019
calendar year and provide ongoing liquidity for a busy 2020 clinical agenda. Our clinical program
next year for Veyonda® is extremely exciting and appropriately ambitious. It is an integrated
strategy focused on bringing Veyonda® to market in the shortest time possible, plus maximising
its market uptake following approval.’

Under the terms of the recent funding facility entered into by the Company, it also will use $1.5M
from the rebate to reduce its current $4M convertible note funding facility, bringing that Note
back to $2.5M and with it, a significantly lower dilutionary effect when the Note’s 6-month lock
matures early-2020.

Read the full media release here.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The
Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spinoff company developing a pipeline of non-oncology drugs.

About Veyonda®

Veyonda® (previously known as NOX66) is a suppository dosage formulation of the experimental anti-cancer drug,
idronoxil, that leads in the body to the formation of a proprietary pro-drug form. Idronoxil specifically inhibits the
ability of cancer cells to respond to stress, such as that induced by radiation, leading to loss of pro-survival signaling
via sphingosine-1-phosphate. Idronoxil also promotes the STING mechanism, thereby activating the body’s innate
immune system.

www.noxopharm.com

Investor & Corporate Enquiries: Company Secretary:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Media Contact USA: 
Frank de Maria
Purposeful Communications
T: +1 347 647 0284
E: frank.demaria@purposefulcommunications.com

Company Secretary:
David Franks
+61 2 9299 9690
David.Franks@automicgroup.com.au

Media Contact Australia
Marianne Gould
Noxopharm Ltd
T: +61 2 9144 2223
E: Marianne.gould@noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use
words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”,
“plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other
similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by
Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the
forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could
cause the actual results, performance or achievements to differ materially from those expressed or implied by the
forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by
Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance
should not be placed upon such statements.

 

Home

News & opinion

Member Directory

Events